Using Digital Tools To Unpick The Adherence Problem

An ambitious five-year public-private partnership plans to tackle non-adherence to medicines by giving patients EU-wide access to regulator-approved digital drug information. One year in, progress has been made in creating an app that could do just this.

Digital lock opened
• Source: Alamy

As many as a half of patients do not take prescription medicines as prescribed. The Organisation for Economic Co-operation and Development estimates that around 200,000 premature deaths annually in Europe relate to poor medication adherence, which may cost as much as €125bn each year in avoidable hospitalization, emergency care and adult outpatient visits. While there is currently no comprehensive understanding of all the factors that influence patients’ decisions regarding treatment adherence, an EU-funded project hopes to demonstrate that by making information on medicines more accessible and understandable, patients will be more likely to take their medicines correctly, resulting in better health outcomes and quality of life.

The public-private partnership Gravitate-Health group, backed by the EU Innovative Medicines Initiative (IMI2), has the ambitious aim of delivering a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Market Access

PBMs Tighten The Reins: Value Becomes The New Access Gatekeeper

 
• By 

Facing rising costs and tighter regulations, PBMs and insurers are accelerating the shift to value-based drug coverage, demanding stronger proof of therapeutic and economic benefit from pharma.

Mapping The Power And Potential Of Europe’s Market Access Collaborations

 
• By 

Understand who’s influencing access decisions and how pharma can engage strategically across the continent.

Q&A: Commercializing Oncology Products, Strategic Insights For Drug Developers

 
• By 

John Arena, president of Global Pharma Services at Cencora, talks to In Vivo about how companies can strategize market entry for oncology products.

CRL Trio Brings Shifting Sand To Regenerative Medicine Regulation

 

Replimune's RP1 oncolytic immunotherapy became the third regenerative medicine to receive an FDA complete response letter this month as the agency appears to re-visit previous agreements about accelerated approval.

More from In Vivo

Podcast: Tevard CEO Sees Hope For His Daughter In Company’s tRNA Platform

 
• By 

Tevard Biosciences CEO Daniel Fischer discusses how engineered suppressor tRNAs overcome nonsense mutations, restoring full-length protein production to treat rare genetic diseases like Dravet syndrome.

Execs On The Move: July 2025

 
• By 

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Deals In Depth: July 2025

 
• By 

Six $1bn+ alliances were penned in July, and two exceeded $2bn.